All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386,Apalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
Details:
Janssen may sponsor and conduct up to two Phase 1/2 studies evaluating the combination of EPI-7386 and apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with mCRPC who have failed second-generation antiandrogen therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RP-3500,Talazoparib
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for the treatment of solid tumors with selected genomic alterations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZW25,Docetaxel,Tislelizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
BeiGene has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy for metastatic HER2+ breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SRA737,Momelotinib,Aphidicolin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020
Details:
Scientists found that combining the drug with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-Survivac
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020
Details:
DPX-Survivac generated survivin-specific T cells in the blood of 80% of patients sampled.